ESHRE Guidelines for Endometriosis
The most current ESHRE (European Society of Human Reproduction and Embryology) guidelines from 2022 provide comprehensive, evidence-based recommendations for diagnosis and management of endometriosis, representing a significant update from previous versions with important shifts in diagnostic and treatment approaches 1.
Key Diagnostic Recommendations
The 2022 ESHRE guidelines challenge the traditional gold standard of laparoscopy with histology for diagnosis 1. The guideline now supports:
- Clinical diagnosis based on symptoms (dysmenorrhea, deep dyspareunia, chronic pelvic pain, infertility) without requiring surgical confirmation in many cases
- Imaging modalities (transvaginal ultrasound, MRI) for detecting ovarian endometriomas and deep infiltrating endometriosis
- Empirical hormonal treatment trials without surgical confirmation when symptoms are suggestive
This represents a major departure from requiring laparoscopic confirmation before treatment initiation, acknowledging that surgical diagnosis may delay appropriate therapy and expose patients to unnecessary surgical risks 1, 2.
Pain Management Algorithm
First-Line Medical Treatment
For endometriosis-associated pain, hormonal suppression is the cornerstone of medical management 1:
- Combined oral contraceptives (COCs) - continuous or cyclic regimens
- Progestins - particularly dienogest, which shows superior long-term efficacy with favorable side-effect profiles 3
- Levonorgestrel intrauterine system (LNG-IUS) - especially effective when adenomyosis coexists 3
All hormonal treatments show similar efficacy for pain reduction, but differ in side-effect profiles and cost 4, 1.
Second-Line Medical Treatment
- GnRH agonists for at least 3 months with add-back hormone therapy to prevent bone mineral loss 4
- GnRH antagonists - newer option with similar efficacy but potentially fewer side effects 3
Critical caveat: No medical therapy eradicates endometriotic lesions; they only suppress symptoms during treatment 4.
Surgical Management for Pain
Laparoscopic excision or ablation of endometriotic lesions provides significant pain reduction in the first 6 months post-surgery 4. However:
- Up to 44% experience symptom recurrence within one year 4
- Surgical approach should be tailored to disease location and severity
- Deep infiltrating endometriosis requires referral to specialized centers 2, 5
- LUNA (laparoscopic uterine nerve ablation) adds no additional benefit 2
Infertility Management
Minimal-Mild Endometriosis
Laparoscopic ablation of lesions plus adhesiolysis improves fertility compared to diagnostic laparoscopy alone 2. However:
- Hormonal suppression does NOT improve fertility outcomes 4, 2
- No evidence that medical treatment affects future fertility 4
Moderate-Severe Endometriosis
- Insufficient evidence exists to determine whether surgical excision enhances pregnancy rates 2
- IVF is appropriate treatment, especially with coexisting infertility factors or failed prior treatments 2
- IVF pregnancy rates are lower in endometriosis patients compared to tubal factor infertility 2
Disease-Specific Considerations
Asymptomatic Endometriosis
Expectant management is appropriate since endometriosis may regress spontaneously and is unpredictable 4, 1.
Severe/Deep Infiltrating Endometriosis
- Medical treatment alone is insufficient 4
- Requires multidisciplinary surgical expertise 2, 5
- Preoperative imaging (MRI, transvaginal ultrasound) essential for surgical planning 5
Adolescents
The 2022 guidelines specifically address adolescent endometriosis, recommending early empirical treatment to prevent disease progression and improve quality of life 1.
Post-Hysterectomy/Oophorectomy
Hormone replacement therapy with estrogen is NOT contraindicated following hysterectomy and bilateral salpingo-oophorectomy for endometriosis 4.
Important Clinical Pitfalls
- Pain severity does not correlate with disease extent - minimal disease can cause severe pain and vice versa 4
- Depth of lesions correlates better with pain than lesion type 4
- No medical therapy prevents disease progression or improves long-term fertility 4
- High recurrence rates after surgery necessitate long-term management planning 4
- CA-125 has limited diagnostic utility, especially in minimal-mild disease 4
Evidence Quality Note
The 2022 ESHRE guidelines 1 acknowledge that 32 of 83 recommendations are based on expert opinion (Good Practice Points) rather than high-quality evidence, highlighting significant knowledge gaps requiring further research. The guidelines provide 109 total recommendations covering diagnosis, pain management, infertility treatment, recurrence prevention, and special populations 1.
The guideline emphasizes individualized treatment based on symptom severity, fertility desires, disease extent, and patient preferences, while prioritizing quality of life outcomes 1, 6.